Refine by
Hiv Integrase Protein Inhibitor 1 Articles & Analysis
11 news found
Frontier Biotechnologies announced that the Azerbaijan Republic Ministry of Health approved Aikening® (Albuvirtide), the first long-acting intravenous infusion for the treatment of HIV-1 infection in adults. Aikening® is a new fusion inhibitor given once weekly, used in combination dual therapy to treat people living with HIV who have failed initial treatment. The approval of ...
During the quarter ended 31 March 2022 Biotron Limited (‘Biotron’ or ‘the Company’) achieved key outcomes including: Confirmed and extended previous findings on the effectiveness of Biotron's lead antiviral drug BIT225 against SARS-CoV-2 in an animal model of human COVID-19 through demonstration of 100% survival despite administration of a lethal dose of the virus. ...
Frontier Biotech (stock code: 688221.SH) announces that it signs an agreement with R-Pharm, JSC, one of the largest pharmaceutical companies in Russia, for registration and commercialization of Aikening® (generic name: Albuvirtide) in Russia. Cheryl Tan, Global Head of Frontier Biotech's International Businesses, said, “Aikening® is the first new long-acting antiretroviral drug ...
The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting HIV-1 fusion inhibitor, Aikening® (generic name: Albuvirtide [ABT]) in an all-Asian population TALENT ...
Creative Enzymes, a professional enzyme provider located in New York, always hammers at researches and trials in order to provide customers with various enzyme products and services as many as possible. Creative Enzymes has recently launched Tn5 Transposase for researchers. With more than ten-year experience in offering professional services and high-quality products for academic use and ...
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today announced the results of their Phase 1 study of OB-002H which is an investigational candidate microbicide for HIV prevention. The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of OB-002H ...
Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific MAS Omni Infectious Disease quality control sets for monitoring serological assays for analytes such as HIV 1&2, Hepatitis B & C virus, Syphilis and HTLV I/II. Serology testing for infectious diseases continues to be on the rise and newer instrument platforms are ...
As scientists scramble to learn more about the SARS-CoV-2 coronavirus, two recent studies of the virus’ genome reached controversial conclusions: namely, that snakes are intermediate hosts of the new virus, and that a key coronavirus protein shares “uncanny similarities” with an HIV-1 protein. Now, a study in ACS’ Journal of Proteome Research refutes both ideas and ...
Investigators discuss in "a(1)Proteinase Inhibitor Regulates CD4 Lymphocyte Levels and Is Rate Limiting in HIV-1 Disease" new findings in HIV/AIDS. According to the authors of recent research from New York City, New York, "The regulation of adult stem cell migration through human hematopoietic tissue involves the chemokine CXCL12 (SDF-1) and its receptor CXCR4 (CD184). In addition, human ...
Abbott and the Clinton Health Access Initiative (CHAI) have joined forces to provide HIV testing to infants in all countries working in partnership with the CHAI. A key focus of this cooperation will be sub-Saharan Africa, which the World Health Organization estimates to account for 90 percent of global HIV infections in children. Under terms of the agreement, Abbott will supply its RealTime ...
According to recent research from New York, HLE "interacts with HIV-1 glycoprotein (gp)41, suggesting a nonenzymatic receptor function for HLE in the context of HIV-1." "HLE is found localized to the cell surface, but not granules in HIV permissive clones, and to granules, but not the cell surface of HIV nonpermissive clones," noted C.L. Bristow and coauthors at Rockefeller ...